908 Devices (NASDAQ:MASS) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• 908 Devices has received a "Sell (D-)" rating from Weiss Ratings, indicating a negative outlook on the stock.
• The stock's recent performance shows a trading price of $8.62, up 2.6%, but it has a negative EPS and significant decrease in net margins.
• Despite the negative rating, other analysts have issued a consensus rating of "Moderate Buy" with an average target price of $8.00.

908 Devices (NASDAQ:MASS - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by investment analysts at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

A number of other analysts have also recently weighed in on MASS. Leerink Partners raised shares of 908 Devices from a "market perform" rating to an "outperform" rating and set a $12.00 target price on the stock in a report on Tuesday, August 5th. Wall Street Zen raised shares of 908 Devices from a "sell" rating to a "hold" rating in a report on Monday, September 15th. Finally, Leerink Partnrs raised shares of 908 Devices from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, 908 Devices currently has a consensus rating of "Moderate Buy" and an average target price of $8.00.

908 Devices Trading Up 2.6%

NASDAQ MASS traded up $0.22 during trading hours on Friday, reaching $8.62. 67,115 shares of the company traded hands, compared to its average volume of 1,265,177. 908 Devices has a 12 month low of $1.81 and a 12 month high of $9.34. The stock has a market capitalization of $309.15 million, a PE ratio of -16.01 and a beta of 0.46. The company has a 50 day moving average of $7.23 and a two-hundred day moving average of $6.45.

908 Devices (NASDAQ:MASS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.02). The company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $12.17 million. 908 Devices had a negative net margin of 30.54% and a negative return on equity of 24.30%. 908 Devices has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that 908 Devices will post -1.99 earnings per share for the current year.

Insider Transactions at 908 Devices

In related news, CFO Joseph H. Iv Griffith sold 5,000 shares of the stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $7.07, for a total value of $35,350.00. Following the completion of the transaction, the chief financial officer owned 97,930 shares in the company, valued at $692,365.10. This represents a 4.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 10,000 shares of company stock valued at $80,593. Corporate insiders own 23.70% of the company's stock.

Hedge Funds Weigh In On 908 Devices

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers grew its position in 908 Devices by 5.5% in the 2nd quarter. Rhumbline Advisers now owns 36,416 shares of the company's stock valued at $260,000 after buying an additional 1,894 shares in the last quarter. Bank of New York Mellon Corp grew its position in 908 Devices by 4.0% in the 1st quarter. Bank of New York Mellon Corp now owns 51,915 shares of the company's stock valued at $233,000 after buying an additional 1,985 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its position in 908 Devices by 49.7% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,558 shares of the company's stock valued at $47,000 after buying an additional 2,176 shares in the last quarter. Nisa Investment Advisors LLC grew its position in 908 Devices by 453.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,784 shares of the company's stock valued at $27,000 after buying an additional 3,100 shares in the last quarter. Finally, Farther Finance Advisors LLC bought a new position in 908 Devices in the 3rd quarter valued at about $28,000. Institutional investors own 88.06% of the company's stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.